Practice changing clinical trials in NET
Dr. Joakim Crona provides an overview of practice changing clinical trials within the field of neuroendocrine tumours and neuroendocrine carcinomas
Hello on behalf of CORONARY CONNECT my name is Jan Přeček. I'm a cardiologist from the University Hospital Olomouc in the Czech Republic.
I'd like to talk about safety of low levels of LDL cholesterol (LDL-C).
LDL-C as a Risk Factor
Elevated LDL-C is a clearly established major risk factor for the development of atherosclerotic cardiovascular disease.
Risk reduction of atherosclerotic cardiovascular disease is proportional to the absolute and relative LDL-C reduction achieved.
In other words, there seems to be no LDL-C threshold, below which no further atherosclerotic cardiovascular disease prevention can be achieved.
Please respond on a scale of 1 to 5 (5=strongly agree).